KR102265902B1 - Composition for relieving swelling, the spray dryer and the menufacturing method - Google Patents

Composition for relieving swelling, the spray dryer and the menufacturing method Download PDF

Info

Publication number
KR102265902B1
KR102265902B1 KR1020200165231A KR20200165231A KR102265902B1 KR 102265902 B1 KR102265902 B1 KR 102265902B1 KR 1020200165231 A KR1020200165231 A KR 1020200165231A KR 20200165231 A KR20200165231 A KR 20200165231A KR 102265902 B1 KR102265902 B1 KR 102265902B1
Authority
KR
South Korea
Prior art keywords
powder
drying chamber
piston
raw material
weight
Prior art date
Application number
KR1020200165231A
Other languages
Korean (ko)
Inventor
이보희
Original Assignee
주식회사 티르티르
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 티르티르 filed Critical 주식회사 티르티르
Priority to KR1020200165231A priority Critical patent/KR102265902B1/en
Application granted granted Critical
Publication of KR102265902B1 publication Critical patent/KR102265902B1/en

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
    • A61K36/725Ziziphus, e.g. jujube
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/23Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232Angelica
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/287Chrysanthemum, e.g. daisy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/42Cucurbitaceae (Cucumber family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/75Rutaceae (Rue family)
    • A61K36/752Citrus, e.g. lime, orange or lemon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/80Scrophulariaceae (Figwort family)
    • A61K36/804Rehmannia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/906Zingiberaceae (Ginger family)
    • A61K36/9068Zingiber, e.g. garden ginger
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

An object of the present invention is to obtain a composition having an excellent diuretic effect by increasing urine excretion and sodium excretion by using a herbal mixture with few side effects and a method for preparing the same. To achieve the above object, the method of the present invention comprises: an input step of inputting the raw material into an extractor (S10); an immersion step of extracting the raw material in the extractor at a temperature of 95 to 105°C for 7 to 9 hours, and then immersing the same again for 14 to 16 hours (S20); a first filtering step of filtering the immersed raw material in a filter of 140 to 160 mesh (S30); a concentration step of concentrating the filtered raw material to a solid content of 19 to 21 wt% (S40); a mixing step of mixing 34 to 36 wt% of dextrin with 64 to 66 wt% of the plant mixed concentrate, which is the concentrated raw material, to make a mixed solution (S50); a powder step of powdering the mixed solution using a spray dryer (100) (S60); and, a second filtering step of filtering the powder using a filter (S70). By the above configuration, the amount of urine excretion and the amount of sodium excretion are increased more, so as to provide an excellent diuretic effect and very effectiveness in alleviating swelling.

Description

붓기 개선용 조성물과 그 조성물의 생성에 사용되는 분무건조기 및 그 제조방법{COMPOSITION FOR RELIEVING SWELLING, THE SPRAY DRYER AND THE MENUFACTURING METHOD}A composition for improving swelling, a spray dryer used in the production of the composition, and a manufacturing method thereof {COMPOSITION FOR RELIEVING SWELLING, THE SPRAY DRYER AND THE MENUFACTURING METHOD}

본 발명은 붓기 개선용 조성물에 관한 것으로, 특히 대추, 생강, 건호박, 지황, 당귀뿌리, 팥, 국화, 진피, 대나무잎, 서목태를 포함하는 생약혼합물의 추출물을 유효성분으로 함유하는 붓기 개선용 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a composition for improving swelling, and in particular, for improving swelling containing an extract of a herbal mixture including jujube, ginger, dried pumpkin, rehmannia, angelica root, red bean, chrysanthemum, dermis, bamboo leaf, and seomoktae as an active ingredient It relates to a composition and a method for preparing the same.

부종은 수분대사의 이상으로 체액분포에 이상이 생겨 세포사이의 간질에 수분과 염분이 과다하게 축적된 상태를 말하며 신장이나 심장의 기능부전, 혹은 간장질환이 있을 때 주로 나타나며 단백질의 부족에 의해서도 나타날 수 있다. 즉, 폐장, 비장, 신장의 세 장기가 관여하는 기의 승강작용, 숙강작용, 증화작용이 잘 이루어지지 않을 때 일어나는 질환으로 보는 것이다. Edema refers to a condition in which water and salt are excessively accumulated in the interstitium between cells due to an abnormality in the distribution of fluid due to abnormal water metabolism. It occurs mainly when there is a malfunction of the kidney or heart, or liver disease. It can also be caused by a lack of protein. can In other words, it is regarded as a disease that occurs when the three organs, the lung, spleen, and kidney, do not perform well.

또한 특별히 원인질환을 발견할 수 없는 특발성 부종의 경우는 특히 여성에게 많이 나타나게 되는데, 이는 남성에 비해 음의 기운을 많이 가지는 여성이 기의 순환이 잘 되지 않고 한곳에 뭉쳐 울체되는 경우가 많고 기가 울체되면 몸속의 수분 또한 순환이 저하되어 부종으로 나타나게 되는 경우가 많기 때문이다. 이러한 여성부종은 일반적인 부종의 증상 외에 동반되는 증상으로 생리전후, 배란기, 출산 전후로 더욱 심해진다. In addition, the case of idiopathic edema for which a specific cause cannot be found is particularly common in women. This is because women who have a lot of negative energy compared to men do not have good circulation of qi and are often stagnant in one place. This is because the circulation of water in the body is also lowered and edema appears in many cases. This female edema is a symptom that accompanies the symptoms of general edema and gets worse before and after menstruation, ovulation, and before and after childbirth.

특히, 산전산후부종(産前産後浮腫)은 여성이 출산 전과 출산 후에 생기는 부종으로서, 몸이 붓는 현상을 말한다. 산전산후의 부종의 원인은 출산 전후과정의 피로, 스트레스, 호르몬의 작용으로 인해 우리 몸에 나트륨이 축적되면서 발생하거나, 또는 운동량이 부족하여 원활한 혈액 순환이 이루어지지 않아 더욱 심해지며, 자궁이나 회음부위 또는 제왕절개 부위에 염증반응으로 나타나기도 한다.In particular, prenatal and postpartum edema (産前産下浮腫) is the swelling that occurs before and after childbirth in women, and refers to swelling of the body. The cause of prenatal and postpartum edema is caused by the accumulation of sodium in our body due to fatigue, stress, and the action of hormones before and after childbirth, or it worsens due to lack of exercise and poor blood circulation, making it worse in the uterus or perineum. Or it may appear as an inflammatory reaction at the cesarean section.

이러한 붓기를 완화하는 종래의 기술로는 대한민국 등록특허공보 제10-2074192호의 "호박씨, 비트, 마카 및 아로니아를 이용한 부종 예방 및 개선용 조성물의 제조방법 및 그 조성물"이 있으나, 이는 그 원재료가 한국 토산물이 아닌 것이 많아 한국인의 체질에 부적합한 면이 있었고, 주변에서 쉽게 채취할 수 있는 재료가 아닌 문제점이 있었다.As a conventional technique for alleviating such swelling, there is "a method of manufacturing a composition for preventing and improving edema using pumpkin seeds, beets, maca and aronia and its composition" of Korean Patent Publication No. 10-2074192, but this There were some aspects that were not suitable for the constitution of Koreans because there were many non-Korean products, and there was a problem that it was not a material that could be easily collected from the surrounding area.

대한민국 등록특허공보 제10-2074192호의 "호박씨, 비트, 마카 및 아로니아를 이용한 부종 예방 및 개선용 조성물의 제조방법 및 그 조성물""Method for preventing and improving edema using pumpkin seeds, beets, maca and aronia, and composition thereof" in Korean Patent Publication No. 10-2074192

본 발명은 부작용이 적은 생약혼합물을 이용하여 요 배설량과 나트륨 배설량이 증가시킴으로써 이뇨효과가 우수한 조성물 및 그 제조방법을 얻는 것을 목적으로 한다.An object of the present invention is to obtain a composition having excellent diuretic effect and a method for preparing the same by increasing urine excretion and sodium excretion by using a herbal mixture with few side effects.

또한 본 발명은 분무건조를 실행할 경우 뜨거운 공기와 함께 내압을 줄임으로써 매우 효율적인 건조가 가능한 조성물 및 그 제조방법을 얻는 것을 목적으로 한다.Another object of the present invention is to obtain a composition capable of very efficient drying by reducing internal pressure together with hot air when spray drying is performed, and a method for preparing the same.

본 발명은 상기와 같은 목적을 달성하기 위해, 원재료를 추출기에 투입하는 투입단계(S10); 상기 추출기에서 원재료를 95~105℃의 온도로 7~9시간동안 추출 후, 다시 14~16시간 동안 침지하는 침지단계(S20); 상기 침지한 원재료를 140~160메쉬의 여과기에서 여과하는 제1 여과단계(S30); 상기 여과된 원재료를 고형분 19~21중량%까지 농축시키는 농축단계(S40); 상기 농축된 원재료인 식물혼합농축액 64~66중량%에 덱스트린 34~36중량%를 혼합하여 혼합액을 만드는 혼합단계(S50); 상기 혼합액을 분무건조기를 이용하여 분말화하는 분말단계(S60); 및, 상기 분말을 여과기를 이용하여 여과하는 제2 여과단계(S70)를 진행할 수 있다.The present invention, in order to achieve the above object, the input step of inputting the raw material to the extractor (S10); An immersion step (S20) of extracting the raw material in the extractor at a temperature of 95 to 105° C. for 7 to 9 hours, and then immersing it again for 14 to 16 hours; A first filtering step (S30) of filtering the immersed raw material in a filter of 140 to 160 mesh; a concentration step (S40) of concentrating the filtered raw material to a solid content of 19 to 21% by weight; A mixing step (S50) of mixing 34 to 36 wt% of dextrin with 64 to 66 wt% of the plant mixed concentrate, which is the concentrated raw material, to make a mixed solution (S50); A powder step (S60) of powdering the mixed solution using a spray dryer; And, a second filtering step (S70) of filtering the powder using a filter may be performed.

특히 여기서 상기 식물혼합농축액은, 정제수가 92.50~92.51중량%; 대추가 2.36~2.37중량%; 호박이 1.18~1.19중량%; 생강이 0.78~0.79중량%; 돌콩씨앗이 0.63~0.64중량%; 지황뿌리가 0.55~0.56중량%; 및, 참당귀뿌리, 팥, 국화, 귤나무열매껍질 및 대나무잎이 각각 0.39~0.40중량%;를 포함하여 이루어진 것을 특징으로 한다.In particular, wherein the plant mixture concentrate, purified water 92.50 ~ 92.51% by weight; Jujube 2.36-2.37 wt%; Pumpkin 1.18 to 1.19 wt%; Ginger 0.78-0.79 wt%; Dolphin seeds 0.63 to 0.64% by weight; 0.55 to 0.56% by weight of Rehmannia root; and 0.39 to 0.40% by weight of each Angelica root, red bean, chrysanthemum, tangerine fruit peel, and bamboo leaf;

한편 상기 참당귀뿌리 대신에 유근피를 사용하여도 좋다.On the other hand, you may use eugeunpi instead of the root Angelica Root.

또한 상기 분무건조기는, 천장에는 액체를 분출하는 아토마이저가 구비되고, 최하단에는 분말배출구가 형성되며, 상기 분말배출구보다 위에 위치하면서 가스가 빠져나가는 가스배출구가 형성된 원통형의 밀폐된 건조챔버; 및, 상기 건조챔버 내에서 상하운동을 함으로써 내압을 조절하고 상판과 하판으로 이루어지며, 상기 상판은 상면이 한쪽으로 기울어지고 상방으로 하나 이상의 방열핀이 구비되며, 상기 하판 내부는 전기적으로 연결된 열선이 구비된 피스톤;을 포함하는 것을 특징으로 한다.In addition, the spray dryer, the ceiling is provided with an atomizer for ejecting a liquid, a powder outlet is formed at the lowermost end, the airtight cylindrical drying chamber is located above the powder outlet and formed with a gas outlet through which the gas exits; And, by moving up and down in the drying chamber, the internal pressure is adjusted and the upper plate and the lower plate are formed. The upper plate is inclined to one side and is provided with one or more heat dissipation fins upward, and the lower plate is provided with an electrically connected heating wire. It is characterized in that it includes a piston;

또한 본 발명에서는, 고형분이 19~21 중량%인 식물혼합농축액 64~66중량%에 덱스트린 34~36중량%;를 혼합하여 이루어지되, 상기 식물혼합농축액은, 정제수가 92.50~92.51중량%; 대추가 2.36~2.37중량%; 호박이 1.18~1.19중량%; 생강이 0.78~0.79중량%; 돌콩씨앗이 0.63~0.64중량%; 지황뿌리가 0.55~0.56중량%; 및, 참당귀뿌리, 팥, 국화, 귤나무열매껍질 및 대나무잎이 각각 0.39~0.40중량%;를 포함하여 이루어진 것을 특징으로 하는 붓기 개선용 조성물이 제공된다.Also, in the present invention, 34 to 36% by weight of dextrin is mixed with 64 to 66% by weight of a plant mixture concentrate having a solid content of 19 to 21% by weight; the plant mixture concentrate is purified water 92.50 to 92.51% by weight; Jujube 2.36-2.37 wt%; Pumpkin 1.18 to 1.19 wt%; Ginger 0.78-0.79 wt%; Dolphin seeds 0.63 to 0.64% by weight; 0.55 to 0.56% by weight of Rehmannia root; and 0.39 to 0.40% by weight of each Angelica root, red bean, chrysanthemum, tangerine fruit peel and bamboo leaf, respectively; is provided a composition for improving swelling, characterized in that it comprises.

나아가 상기 참당귀뿌리 대신에 유근피를 사용하여도 좋다.Furthermore, you may use eugeunpi instead of the root of Angelica keiskei.

상기와 같은 구성에 의하여, 요 배설량과 나트륨 등의 배설량을 더 많이 증가시켜서 이뇨효과가 우수하여 붓기 개선에 매우 효과적이다.By the above configuration, the amount of urine excretion and the amount of sodium, etc. excreted more is increased, so that the diuretic effect is excellent, and thus it is very effective in improving swelling.

또한 본 발명의 제조방법에 사용되는 분말건조기에 의하면 외부에서 따로 뜨거운 공기(H)를 주입할 필요없이 피스톤에 의하여 효율적으로 기화시킴으로써 건조된 분말을 손쉽게 얻을 수 있는 유리한 효과가 있다.In addition, according to the powder dryer used in the manufacturing method of the present invention, there is an advantageous effect that a dried powder can be easily obtained by efficiently vaporizing by a piston without the need to separately inject hot air (H) from the outside.

도 1은 본 발명의 붓기 개선용 조성물의 제조방법을 수행하는 흐름도이다.
도 2는 본 발명의 붓기 개선용 조성물을 사용한 실험 중 실험용 쥐의 체중변화를 나타낸 그래프이다.
도 3은 본 발명의 붓기 개선용 조성물을 사용한 실험 중 실험용 쥐의 요량을 측정한 그래프이다.
도 4(a)내지 도 4(c)는 본 발명의 붓기 개선용 조성물을 사용한 실험용 쥐의 요 전해질 검사한 결과 중 각각 Na, K, Cl 량을 측정한 그래프들이다.
도 5는 종래의 분무건조기를 나타내는 개념도이다.
도 6은 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 피스톤을 나타낸 사시도이다.
도 7은 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기의 피스톤이 최상에 위치한 경우의 측면도이다.
도 8은 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기의 피스톤이 중간에 위치한 경우의 측면도이다.
도 9는 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기의 피스톤이 최하단에 위치한 경우의 측면도이다.
1 is a flow chart for performing a method of manufacturing a composition for improving swelling of the present invention.
2 is a graph showing changes in body weight of experimental mice during an experiment using the composition for improving swelling of the present invention.
Figure 3 is a graph measuring the urine volume of experimental mice during the experiment using the composition for improving swelling of the present invention.
4(a) to 4(c) are graphs of Na, K, and Cl amounts, respectively, among the urine electrolyte test results of laboratory mice using the composition for improving swelling of the present invention.
5 is a conceptual diagram showing a conventional spray dryer.
6 is a perspective view showing a piston used in the method of manufacturing the composition for improving swelling of the present invention.
7 is a side view when the piston of the powder dryer used in the method for manufacturing the composition for improving swelling of the present invention is positioned at the top.
8 is a side view when the piston of the powder dryer used in the method for preparing the composition for improving swelling of the present invention is located in the middle.
9 is a side view when the piston of the powder dryer used in the method for preparing the composition for improving swelling of the present invention is located at the bottom.

본 발명의 상기와 같은 목적, 특징 및 다른 장점들은 첨부도면을 참조하여 본 발명의 바람직한 실시 예를 상세히 설명함으로써 더욱 명백해질 것이다. 이하, 첨부된 도면을 참조하여 본 발명의 실시예 및 실험에 따른 붓기 개선용 조성물 및 그 제조방법을 상세히 설명하기로 한다.The above objects, features and other advantages of the present invention will become more apparent by describing preferred embodiments of the present invention in detail with reference to the accompanying drawings. Hereinafter, with reference to the accompanying drawings, a composition for improving swelling and a method for manufacturing the same according to examples and experiments of the present invention will be described in detail.

도 1은 본 발명의 붓기 개선용 조성물의 제조방법을 수행하는 흐름도이다.1 is a flow chart for performing a method of manufacturing a composition for improving swelling of the present invention.

먼저, 원재료를 추출기에 투입하는 투입단계(S10)를 진행한다.First, the input step (S10) of putting the raw material into the extractor proceeds.

상기 원재료는 정제수, 대추, 호박, 생강, 돌콩씨앗, 지황뿌리, 참당귀뿌리, 팥, 국화, 귤나무열매껍질 및 대나무잎이다. 다만 참당귀뿌리 대신에 이뇨작용이 탁월한 유근피를 사용해도 좋다.The raw materials are purified water, jujube, pumpkin, ginger, stone bean seeds, rehmannia root, chrysanthemum root, red bean, chrysanthemum, mandarin orange peel and bamboo leaf. However, you can use yugunpi, which has excellent diuretic effect, instead of chamangwi root.

다음으로, 상기 추출기에서 원재료를 95~105℃의 온도로 7~9시간동안 추출 후, 다시 14~16시간 동안 침지하는 침지단계(S20)를 진행한다.Next, in the extractor, the raw material is extracted at a temperature of 95 to 105° C. for 7 to 9 hours, followed by an immersion step (S20) of immersion for 14 to 16 hours again.

다음으로, 상기 침지한 원재료를 140~160메쉬의 여과기에서 여과하는 제1 여과단계(S30)를 진행한다.Next, a first filtering step (S30) of filtering the immersed raw material in a filter of 140 to 160 mesh is performed.

다음으로, 상기 여과된 원재료를 고형분 19~21중량%까지 농축시키는 농축단계(S40)를 진행한다.Next, a concentration step (S40) of concentrating the filtered raw material to a solid content of 19 to 21% by weight is performed.

다음으로, 상기 농축된 원재료인 식물혼합농축액 64~66중량%에 덱스트린 34~36중량%를 혼합하여 혼합액을 만드는 혼합단계(S50)를 진행한다.Next, a mixing step (S50) of making a mixed solution by mixing 34 to 36% by weight of dextrin with 64 to 66% by weight of the plant mixture concentrate, which is the concentrated raw material, is performed.

다음으로, 상기 혼합액을 분무건조기를 이용하여 분말화하는 분말단계(S60) 및, 상기 분말을 여과기를 이용하여 여과하는 제2 여과단계(S70)를 순차적으로 진행한다.Next, a powder step (S60) of powdering the mixed solution using a spray dryer and a second filtration step (S70) of filtering the powder using a filter are sequentially performed.

이후에는 필요에 따라 포장단위를 정하여 포장하는 것이 좋다.After that, it is better to set the packaging unit as needed and pack it.

특히 여기서 상기 식물혼합농축액은, 정제수가 92.50~92.51중량%, 대추가 2.36~2.37중량%, 호박이 1.18~1.19중량%, 생강이 0.78~0.79중량%, 돌콩씨앗이 0.63~0.64중량%, 지황뿌리가 0.55~0.56중량%가 됨이 좋고, 참당귀뿌리, 팥, 국화, 귤나무열매껍질 및 대나무잎이 각각 0.39~0.40중량%를 포함하여 이루어진 것이 좋다.In particular, the plant mixture concentrate here is purified water 92.50 ~ 92.51% by weight, jujube 2.36 ~ 2.37% by weight, pumpkin 1.18 ~ 1.19% by weight, ginger 0.78 ~ 0.79% by weight, stone bean seeds 0.63 ~ 0.64% by weight, rehufu It is good that the root is 0.55 to 0.56 wt%, and it is preferable that the Angelica root, red bean, chrysanthemum, mandarin orange peel, and bamboo leaf are each contained in an amount of 0.39 to 0.40 wt%.

<실험용 쥐를 이용한 실험><Experiment using laboratory mice>

본 시험은 고염식이 사료를 급이한 Sprague-Dawley(SD) 계통 수컷 랫드에게 본 발명의 붓기 개선용 조성물을 경구투여하였을 때 이뇨작용에 미치는 영향을 조사하기 위하여 실시되었다. 정상대조군(일반 사료+멸균증류수), 음성대조군(고염식이 사료+멸균증류수) 및 시험물질 투여군(고염식이 사료+본 발명의 붓기 개선용 조성물 200 및 400 ㎎/㎏/day)으로 시험군을 설정한 후 시험물질을 16 일간 반복투여하였으며, 실험기간 동안 일반증상, 체중변화, 요량, 요 전해질, 그리고 혈액 전해질을 검사하였다.This test was conducted to investigate the effect on diuresis when the composition for improving swelling of the present invention was orally administered to Sprague-Dawley (SD) male rats fed a high-salt diet. Test groups were set as normal control group (normal feed + sterile distilled water), negative control group (high salt diet + sterile distilled water) and test substance administration group (high salt diet + composition for improving swelling of the present invention 200 and 400 mg/kg/day) After that, the test substance was administered repeatedly for 16 days, and general symptoms, weight change, urine output, urine electrolytes, and blood electrolytes were examined during the experiment period.

1. 시험물질의 준비1. Preparation of test substances

조제방법은, 투여 당일 정량의 시험물질을 칭량한 후 멸균증류수에 용해시켜 고용량군의 시험용액을 조제한 후, 이를 희석하는 방법으로 나머지 용량군의 시험용액을 조제하였다. 투여 당일 투여 직전에 조제 후 바로 투여되었기 때문에 안정성 시험은 수행하지 않았다.As for the preparation method, the test solution of the remaining dose group was prepared by weighing a fixed amount of the test substance on the day of administration, dissolving it in sterile distilled water to prepare a high-dose test solution, and then diluting it. Since it was administered immediately after preparation immediately before administration on the day of administration, a stability test was not performed.

조제빈도는, 시험용액의 안정성이 확보되지 않았기 때문에 매일 조제하였다.The preparation frequency was prepared daily because the stability of the test solution was not secured.

2. 시험계2. test system

Sprague-Dawley(SD) 계통 수컷 랫츠를 사용하였으며, 입수 시에는 7주령이었고, 입수 당일 미생물 검사성적서와 동물의 외관을 검사하였다. 입수 후 7일 이상의 순화기간을 두었으며, 순화기간 중 일반증상을 관찰하여 건강한 동물만을 시험에 사용하였다. 시험 시에는 8주령이었다. 입수시 체중범위는 184.49∼204.57g이었고, 시험 시 체중범위는 225.53∼258.33g이었다. 사용 동물수는 총 24마리였다. 투여 전일에 체중을 측정하고 순위화한 체중으로 군분리를 실시하였다. 평균체중의 ±20% 범위 내에 속하는 동물만을 시험에 사용하였다.Male rats of Sprague-Dawley (SD) strain were used, and they were 7 weeks old at the time of acquisition, and the microbiological test report and appearance of the animals were examined on the day of acquisition. After acquisition, an acclimatization period of more than 7 days was provided, and only healthy animals were used for the test by observing general symptoms during the acclimatization period. At the time of testing, he was 8 weeks old. The body weight range at the time of acquisition was 184.49 ~ 204.57 g, and the weight range at the time of the test was 225.53 ~ 258.33 g. A total of 24 animals were used. The body weight was measured on the day before administration, and group separation was performed according to the ranked body weight. Only animals falling within the range of ±20% of the mean body weight were used for the test.

3. 동물실 및 사육환경3. Animal room and breeding environment

동물실의 온도는 22±3 ℃, 상대습도는 50±20%RH였고, 환기횟수는 10∼15 회/hr였으며, 명암 cycle은 형광등조명 12 hr(08:00 점등∼20:00 소등)이었다. 조도는 150∼300 Lux, 소음은 60 db 이하, 암모니아 농도는 15 ppm 이하였다. 사육상자 및 사육밀도에 있어서는, 검역, 순화, 투여 및 관찰기간 중 스테인레스제 망사육상자(250W × 350L × 180H㎜)에 3 마리 이하로 수용하였다. 사육상자의 교체는 군분리 시 실시하였다. 사료 및 물(KCL/ANI/008, 015)에 있어서는, 일반 사료(Teklad Certified Irradiated Global 18% Protein Rodent Diet, Envigo, USA)와 고염식이 사료(Teklad Custom Diet, 4% NaCl Diet, Envigo, USA)를 급이기에 넣고 자유섭취시켰고, 물은 음용 상수도수를 정수시킨 후 폴리카보네이트제 물병에 넣고 자유섭취시켰다.The temperature of the animal room was 22±3 ℃, the relative humidity was 50±20%RH, the number of ventilation was 10 to 15 times/hr, and the light-dark cycle was 12 hr for fluorescent lighting (08:00 on to 20:00 off). . Illuminance was 150-300 Lux, noise was less than 60 db, and ammonia concentration was less than 15 ppm. In the breeding box and breeding density, no more than 3 animals were housed in a stainless steel mesh breeding box (250W×350L×180Hmm) during quarantine, acclimatization, administration and observation period. The breeding box was replaced during group separation. For feed and water (KCL/ANI/008, 015), standard diet (Teklad Certified Irradiated Global 18% Protein Rodent Diet, Envigo, USA) and high-salt diet (Teklad Custom Diet, 4% NaCl Diet, Envigo, USA) was put into a feeder and consumed freely, and water was purified by drinking tap water and then placed in a polycarbonate water bottle and consumed freely.

4. 시험방법4. Test method

경구투여, 시험동물의 두경배부 피부를 잡아 보정한 후 경구투여용 존데를 이용하여 강제 경구투여 하였다. 투여횟수 및 시각은 1 회/일, 7 일/주, 16 일간, 매일 오전 중에 투여하였고, 투여액량은 가장 최근에 측정한 체중을 기준으로 10 ㎖/㎏/day으로 투여액량을 계산하였다. 동물모델 유도는, 군분리를 실시한 후 투여기간 동안 정상 대조군의 시험동물에는 일반사료를, 음성 대조군 및 시험물질 투여군의 시험동물에는 고염식이 사료를 급이하였다.Oral administration, after correcting the skin of the head and neck of the test animal, it was forcibly administered orally using a sonde for oral administration. The frequency and time of administration were 1 time/day, 7 days/week, 16 days, and every morning in the morning, and the dose was calculated as 10 ml/kg/day based on the most recently measured body weight. For animal model induction, during the administration period after group separation, normal feed was given to the test animals of the normal control group, and a high-salt diet was fed to the test animals of the negative control group and the test substance-administered group.

Figure 112020129553416-pat00001
Figure 112020129553416-pat00001

[표 1]은 시험군의 구성을 나타낸 것이다. G1은 일반사료와 멸균증류수를 급이한 정상대조군, G2는 고염식이 사료와 멸균증류수를 급이한 음성대조군, G3~G4는 고염식이 사료와 본 발명의 붓기 개선용 조성물을 급이한 시험물질 투여군이다.[Table 1] shows the composition of the test group. G1 is a normal control group fed with general feed and sterilized distilled water, G2 is a negative control group fed with a high-salt diet and sterile distilled water, and G3~G4 is a test substance fed with a high-salt diet and the composition for improving swelling of the present invention. administration group.

5. 시험항목5. Test items

투여 전 기간에 걸쳐 1 일 1 회 투여 직후의 일반증상을 관찰하였다. 일반증상의 관찰은 사망여부, 증상의 종류, 발현일 및 증상의 정도를 개체별로 기록하였다.General symptoms immediately after administration once a day were observed throughout the entire period of administration. For observation of general symptoms, death, type of symptom, onset date, and severity of symptoms were recorded for each individual.

체중은, 모든 동물에 대하여 입수 시, 군 분리 시, 투여개시 시, 투여 후 주 1 회 측정하였다.Body weight was measured at the time of acquisition, at the time of group separation, at the start of administration, and once a week after administration for all animals.

요검사는, 투여 전, 투여 중간 및 투여 종료 시에 모든 시험군의 시험동물을 대사케이지에 동물을 수용한 후 신선뇨를 채집하여 요검사를 실시하였다. 투여 전, 투여 중간 및 투여 종료 시에 모든 시험군의 시험동물을 대사케이지에 동물을 수용한 후 약 24 시간 동안의 요량을 측정하였다. 요 전해질은 채집한 신선뇨를 혈액생화학검사기(Hitachi7180, HITACHI, Japan)를 이용하여 Na(Sodium, 나트륨), K(Potassium, 칼륨) 및 Cl(Chloride,염화물)를 측정하였다. 또한 총 요 전해질 배출량은 측정된 요량과 요 전해질 검사값을 곱하여 산출하였다. For urinalysis, the test animals of all test groups were housed in metabolic cages before, during, and after administration, and fresh urine was collected and urinalysis was performed. Before administration, during administration, and at the end of administration, the test animals of all test groups were accommodated in metabolic cages and then urine output was measured for about 24 hours. For urine electrolytes, Na (Sodium, Sodium), K (Potassium, Potassium) and Cl (Chloride, Chloride) were measured using a blood biochemical tester (Hitachi 7180, HITACHI, Japan). In addition, the total urine electrolyte discharge was calculated by multiplying the measured urine amount and the urine electrolyte test value.

혈액생화학적 검사는, 투여 종료 후 모든 시험동물을 아이소플루레인(Isoflurane)으로 흡입마취하였다. 마취가 확인되면 개복하여 복대동맥으로부터 채혈을 실시한 후 serum separating tube(Sekisui, Insepack)에 넣어 검사에 사용하였다. 혈액전해질 검사는 Serum separating tube의 혈액을 원심분리(3,000 rpm, 10분)하여 얻어진 혈청으로 혈액생화학검사기(Hitachi7180, HITACHI, Japan)를 이용하여 Na(Sodium), K(Potassium) 및 Cl(Chloride)를 측정하였다.For blood biochemical tests, after completion of administration, all test animals were anesthetized by inhalation with Isoflurane. When anesthesia was confirmed, it was opened and blood was collected from the abdominal aorta, and then it was put into a serum separating tube (Sekisui, Insepack) and used for the test. Blood electrolyte test is a serum obtained by centrifugation (3,000 rpm, 10 minutes) of blood in a serum separating tube, using a blood biochemical tester (Hitachi7180, HITACHI, Japan) for Na (Sodium), K (Potassium) and Cl (Chloride). was measured.

6. 자료의 평가 및 통계학적 검정6. Evaluation and Statistical Testing of Data

평균 및 표준편차로 정리하여 경향을 분석하였고, 대조군과 투여군 간의 차이는 독립표본 T 검정(Independent Samples t-Test)과 일원배치 분산분석(one-way ANOVA test)을 이용하여 통계학적으로 검정하였다. 일원배치 분산분석에서 유의성이 인정되고 등분산이 인정되면 Duncan test를, 등분산이 인정되지 않으면 Dunnett’s T3-test를 사용하였다. p<0.05인 경우에 통계학적으로 유의하다고 판정하였으며, 통계학적인 분석은 상용으로 널리 사용되는 통계 패키지인 SPSS 12.0 K 프로그램(SPSS, Chicago, IL, U.S.A.)으로 실시하였다.Trends were analyzed by organizing the mean and standard deviation, and the difference between the control group and the administration group was statistically tested using the Independent Samples t-Test and one-way ANOVA test. Duncan test was used if significance was recognized and equal variance was recognized in one-way ANOVA, and Dunnett's T3-test was used if equal variance was not recognized. When p<0.05, it was determined to be statistically significant, and statistical analysis was performed with the SPSS 12.0 K program (SPSS, Chicago, IL, U.S.A.), which is a commercially widely used statistical package.

7. 실험결과7. Experimental results

[표 2]는 일반증상 및 사망률을 나타낸다.[Table 2] shows general symptoms and mortality.

Figure 112020129553416-pat00002
Figure 112020129553416-pat00002

[표 2]에서 알 수 있듯이, 실험기간 동안 모든 시험군에서 사망동물 및 특이한 일반 증상은 관찰되지 않았다.As can be seen from [Table 2], no dead animals or specific general symptoms were observed in all test groups during the experiment period.

도 2는 본 발명의 붓기 개선용 조성물을 사용한 실험 중 실험용 쥐의 체중변화를 나타낸 그래프이고, [표 3]은 체중변화를 나타낸 표이다.2 is a graph showing the change in body weight of experimental mice during the experiment using the composition for improving swelling of the present invention, and [Table 3] is a table showing the change in body weight.

Figure 112020129553416-pat00003
Figure 112020129553416-pat00003

도 2와 [표 3]에서 알 수 있듯이, 실험 기간 동안 시험군 간 투여군간 통계학적으로 유의한 차이가 관찰되지 않았다.As can be seen from FIG. 2 and [Table 3], no statistically significant difference was observed between the test groups and the administration groups during the experimental period.

도 3은 본 발명의 붓기 개선용 조성물을 사용한 실험 중 실험용 쥐의 요량을 측정한 그래프이고, [표 4]는 요량을 나타낸 표이다.Figure 3 is a graph measuring the amount of urine in laboratory mice during the experiment using the composition for improving swelling of the present invention, [Table 4] is a table showing the amount of urine.

Figure 112020129553416-pat00004
Figure 112020129553416-pat00004

[표 4]와 도 3에서 알 수 있듯이, 실험기간 동안 0, 7 및 15일째에 음성대조군에서 정상대조군에 비하여 통계학적으로 유의한 증가가 관찰되었다. 구체적으로, G1 그룹의 값과 비교하여 G2 그룹의 요량이 유의미하게 증가한 것을 알 수 있다. 한편 [표 4]의 a는 요에 침투되어 작용되는 수분이 있었을 것으로 생각되어서 한 마리의 데이터가 제외된 것을 나타내었다.As can be seen from [Table 4] and FIG. 3, a statistically significant increase was observed in the negative control group compared to the normal control group on days 0, 7 and 15 during the experiment period. Specifically, it can be seen that compared with the value of the G1 group, the urine volume of the G2 group was significantly increased. On the other hand, a in [Table 4] indicates that one animal was excluded because it was thought that there was moisture that penetrated and acted on the urine.

도 4(a)내지 도 4(c)는 본 발명의 붓기 개선용 조성물을 사용한 실험용 쥐의 요 전해질 검사한 결과 중 각각 Na, K, Cl 량을 측정한 그래프들이고, [표 5]는 Na, K, Cl 량을 측정한 표이다.4(a) to 4(c) are graphs measuring the amounts of Na, K, and Cl in the urine electrolyte test results of laboratory mice using the composition for improving swelling of the present invention, respectively, [Table 5] is Na, This is a table in which K and Cl amounts are measured.

Figure 112020129553416-pat00005
Figure 112020129553416-pat00005

도 4(a)내지 도 4(c)와 [표 5]에서 알 수 있듯이, 음성대조군의 7 일째 Na(sodium) 수치가 정상 대조군에 비하여 통계학적으로 유의하게 증가하였고, 7 및 15 일째 K(potassium) 수치가 감소하였다.As can be seen from FIGS. 4(a) to 4(c) and [Table 5], the Na(sodium) level of the negative control group on the 7th day was statistically significantly increased compared to the normal control group, and on the 7th and 15th days K ( potassium) was decreased.

200 ㎎/㎏/day 시험물질 투여군에서 7 및 15 일째에 Na 및 Cl 수치가 음성대조군에 비하여 유의하게 증가하였다. In the 200 mg/kg/day test substance administration group, Na and Cl levels were significantly increased on days 7 and 15 compared to the negative control group.

[표 6]은 본 발명의 붓기 개선용 조성물을 사용한 실험용 쥐의 총 요 전해질 배출량을 나타낸 표이다.[Table 6] is a table showing the total urine electrolyte discharge of experimental rats using the composition for improving swelling of the present invention.

Figure 112020129553416-pat00006
Figure 112020129553416-pat00006

[표 6]에서 알 수 있듯이, 음성대조군의 0, 7 및 15 일째 Na 및 Cl 수치와 0 및 7 일째 K 수치가 정상대조군에 비하여 통계학적으로 유의하게 증가하였다. 200 ㎎/㎏/day 시험물질 투여군에서 15 일째 Na 및 Cl 수치가 음성대조군에 비하여 유의하게 증가하였다. 한편 [표 6]의 a는 요에 침투되어 작용되는 수분이 있었을 것으로 생각되어서 한 마리의 데이터가 제외된 것을 나타내었다.As can be seen from [Table 6], the Na and Cl levels on days 0, 7, and 15 and K values on days 0 and 7 of the negative control group were statistically significantly increased compared to that of the normal control group. In the 200 mg/kg/day test substance administration group, Na and Cl levels were significantly increased on day 15 compared to the negative control group. On the other hand, a in [Table 6] indicates that one animal was excluded because it was thought that there was moisture that penetrated and acted on the urine.

[표 7]은 본 발명의 붓기 개선용 조성물을 사용한 실험용 쥐의 혈액 전해질 검사 결과를 나타낸 표이다.[Table 7] is a table showing the blood electrolyte test results of laboratory mice using the composition for improving swelling of the present invention.

Figure 112020129553416-pat00007
Figure 112020129553416-pat00007

[표 7]에서 알 수 있듯이, 400 ㎎/㎏/day 시험물질 투여군의 Cl 수치가 음성대조군에 비하여 통계학적으로 유의하게 증가하였다.As can be seen from [Table 7], the Cl level of the 400 mg/kg/day test substance administration group increased statistically significantly compared to the negative control group.

8. 결론8. Conclusion

요 전해질 검사에서 200 ㎎/㎏/day 시험물질 투여군에서 7 및 15 일째에 Na 및 Cl 수치가 음성대조군에 비하여 증가하였다. 400 ㎎/㎏/day 시험물질 투여군에서는 유의성은 관찰되지 않았고 200 ㎎/㎏/day 투여군보다 수치가 낮았으나, 음성대조군보다는 Na 및 Cl 수치가 높았다. 요 총 전해질 배출량에서도 이와 유사한 경향의 변화가 관찰되었다. In the urine electrolyte test, the 200 mg/kg/day test substance administration group increased Na and Cl levels on days 7 and 15 compared to the negative control group. Significance was not observed in the 400 mg/kg/day test substance administration group, and the values were lower than the 200 mg/kg/day administration group, but the Na and Cl levels were higher than that of the negative control group. A similar trend was observed in the total urine electrolyte discharge.

따라서 시험물질인 본 발명의 붓기 개선용 조성물은 Na 및 Cl의 요 배출량을 증가시키며 200 ㎎/㎏/day의 용량에서 더 높은 배출효과를 나타내었다. 한편, 랫츠에 높은 농도의 Na를 공급하였을 때 요량, 음수섭취량, Na 배출량 등이 증가한다는 보고가 있어 정상대조군과 음성대조군 간의 차이는 고염식이 사료에 기인한 것으로 판단된다.Therefore, the composition for improving swelling of the present invention, which is a test substance, increases urinary discharge of Na and Cl, and exhibits a higher discharge effect at a dose of 200 mg/kg/day. On the other hand, there is a report that urine volume, drinking water intake, and Na emission increase when a high concentration of Na is supplied to rats, so it is considered that the difference between the normal control group and the negative control group is due to the high-salt diet.

혈액 전해질 검사결과, 400 ㎎/㎏/day 시험물질 투여군의 Cl 수치가 증가하였으나, 생물학적 변동범위 수준의 경미한 변화로 사료된다.As a result of the blood electrolyte test, the Cl level of the 400 mg/kg/day test substance administration group increased, but it is considered to be a slight change in the level of the biological fluctuation range.

이상의 결과로 보아 본 시험 조건에서 고염식이 사료를 급이한 SD 랫츠에 본 발명의 붓기 개선용 조성물을 반복 경구투여하였을 때, Na 및 Cl의 배출 이뇨작용을 증가시키며 400 ㎎/㎏/day 용량보다 200 ㎎/㎏/day 용량에서 더 높은 배출효과를 나타내었다.According to the above results, when the composition for improving swelling of the present invention was repeatedly orally administered to SD rats fed with a high-salt diet in this test condition, the diuretic effect of Na and Cl excretion was increased and higher than the 400 mg/kg/day dose. A higher excretion effect was exhibited at the 200 mg/kg/day dose.

결론적으로 본 발명의 붓기 개선용 조성물은 요 배설량과 나트륨 등의 배설량을 더 많이 증가시켜서 이뇨효과가 우수하여 붓기 개선에 매우 효과적임을 알 수 있었다.In conclusion, it was found that the composition for improving swelling of the present invention was very effective in improving swelling due to its excellent diuretic effect by increasing urine excretion and sodium excretion more.

도 5는 종래의 분무건조기를 나타내는 개념도이다.5 is a conceptual diagram showing a conventional spray dryer.

도 5에서 보면, 종래의 분무건조기(100)는 건조대상이 되는 액체(L)를 아토마이저(11)를 통해 분출하면 뜨거운 공기(H)가 더해져 건조챔버(10) 내부에서 수분이 기화된다. 기화된 가스(G)는 사이클론(15)과 블로워(13)을 통해 외부로 배출되고 분말(P)은 하방으로 배출된다.5 , in the conventional spray dryer 100 , when the liquid L to be dried is ejected through the atomizer 11 , hot air H is added to vaporize the moisture inside the drying chamber 10 . The vaporized gas G is discharged to the outside through the cyclone 15 and the blower 13, and the powder P is discharged downward.

도 6은 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 피스톤을 나타낸 사시도이다.6 is a perspective view showing a piston used in the method of manufacturing the composition for improving swelling of the present invention.

도 6을 보면, 본 발명의 피스톤(20)은 상기 건조챔버(10) 내에서 상하운동을 함으로써 내압을 조절하고 상판(21)과 하판(23)으로 이루어지며, 상기 상판은 상면이 한쪽으로 기울어지고 상방으로 하나 이상의 방열핀(25)이 구비되며, 상기 하판 내부는 전기적으로 연결된 열선(27)이 구비된다. 피스톤이므로 건조챔버내의 내주면에 밀착되어 상하운동함은 당업자에게 자명하다.6, the piston 20 of the present invention adjusts internal pressure by moving up and down in the drying chamber 10 and is composed of an upper plate 21 and a lower plate 23, and the upper plate has an upper surface inclined to one side. One or more heat dissipation fins 25 are provided upwardly, and a heating wire 27 electrically connected to the inside of the lower plate is provided. Since it is a piston, it is obvious to those skilled in the art that it moves vertically in close contact with the inner circumferential surface of the drying chamber.

상판이 한쪽으로 기울어지는 이유는 중력에 의해 분말이 기울어지는 쪽으로 쏟아져 내려가도록 하기 위함이다. 하판내부에는 전기적으로 연결된 열선이 복수회 감겨있어서 건조챔버 내부를 가열하되 상판의 상면에는 방열핀이 하나 이상 구비되어 열발산을 용이하게 한다.The reason the top plate is inclined to one side is to let the powder pour down to the inclined side by gravity. An electrically connected heating wire is wound a plurality of times inside the lower plate to heat the inside of the drying chamber, but one or more heat dissipation fins are provided on the upper surface of the upper plate to facilitate heat dissipation.

도 7은 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기의 피스톤이 최상에 위치한 경우의 측면도이다.7 is a side view when the piston of the powder dryer used in the method for manufacturing the composition for improving swelling of the present invention is positioned at the top.

도 7에서 알 수 있듯이, 본 발명의 분무건조기(100)는 천장에는 액체를 분출하는 아토마이저가 구비되고, 최하단에는 분말배출구(33)가 형성되며, 상기 분말배출구보다 위에 위치하면서 가스가 빠져나가는 가스배출구(35)가 형성된 원통형의 밀폐된 형태이다. 종래의 분무건조기와는 달리 더운 공기(H)가 외부에서 유입되지 않는다.As can be seen from FIG. 7 , the spray dryer 100 of the present invention is provided with an atomizer for ejecting liquid on the ceiling, and a powder outlet 33 is formed at the lowermost end, and the gas is discharged while positioned above the powder outlet. The gas outlet 35 is formed in a closed cylindrical shape. Unlike the conventional spray dryer, hot air (H) does not flow in from the outside.

도 7은 피스톤이 최상에 위치한 경우로서, 액체(L)를 분출하면 건조챔버 내의 온도는 열선의 가열에 의해서만 올라간다. 이때 피스톤이 가스배출구(35)보다 높게 있으므로 내부의 가스는 외부로 배출되지 않는다.7 is a case in which the piston is positioned at the top, and when the liquid L is ejected, the temperature in the drying chamber rises only by heating of the heating wire. At this time, since the piston is higher than the gas outlet 35, the gas inside is not discharged to the outside.

도 8은 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기의 피스톤이 중간에 위치한 경우의 측면도이다.8 is a side view when the piston of the powder dryer used in the method for preparing the composition for improving swelling of the present invention is located in the middle.

피스톤이 내려오면서 내부 압력을 낮추고, 동시에 열선에 의해 건조챔버(10) 내부가 가열되면 기화가 활발하게 일어나는데, 도 8에서의 위치에 오게 되면 기화된 가스는 가스배출구(35)를 통해 빠져나간다. 다만 도 8의 위치에서는 분말배출구(33)가 아직 개구되지 않아 분말이 빠져나가지 못한다.When the piston descends to lower the internal pressure, and at the same time, when the inside of the drying chamber 10 is heated by the heating wire, vaporization occurs actively. When it comes to the position in FIG. 8 , the vaporized gas escapes through the gas outlet 35 . However, in the position of Figure 8, the powder outlet 33 is not yet opened, so that the powder cannot escape.

도 9는 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기의 피스톤이 최하단에 위치한 경우의 측면도이다.9 is a side view when the piston of the powder dryer used in the method for preparing the composition for improving swelling of the present invention is located at the bottom.

피스톤이 최하단에 위치하면 분말배출구(33)가 개구되어 드디어 분말이 외부로 배출된다.When the piston is located at the lowermost end, the powder outlet 33 is opened and the powder is finally discharged to the outside.

이로써 본 발명의 붓기 개선용 조성물의 제조방법에 사용되는 분말건조기에 의하면 외부에서 따로 뜨거운 공기(H)를 주입할 필요없이 피스톤에 의하여 효율적으로 기화시킴으로써 건조된 분말을 손쉽게 얻을 수 있는 유리한 효과가 있다.Accordingly, according to the powder dryer used in the method for preparing the composition for improving swelling of the present invention, there is an advantageous effect that the dried powder can be easily obtained by efficiently vaporizing by the piston without the need to separately inject hot air (H) from the outside. .

상기에서 설명한 바와 같이 본 발명의 과제와 동일한 범위 내에서 다양한 설계 변경을 시도할 수도 있을 것이나, 이러한 설계변경으로 인해 본 발명에서 전혀 예상치 못한 새로운 효과가 나타나지 않는 한, 본 발명의 권리범위를 벗어나지 못할 것이다.As described above, various design changes may be attempted within the same scope as the subject of the present invention, but unless unexpected new effects appear in the present invention due to these design changes, the scope of the present invention cannot be departed from. will be.

S10: 투입단계
S20: 침지단계
S30: 제1 여과단계
S40: 농축단계
S50: 혼합단계
S60: 분말단계
S70: 제2 여과단계
100: 분무건조기
10: 건조챔버
11: 아토마이저
20: 피스톤
21: 상판
23: 하판
25: 방열핀
27: 열선
33: 분말배출구
35: 가스배출구
S10: input stage
S20: immersion step
S30: first filtration step
S40: concentration step
S50: mixing step
S60: powder stage
S70: second filtration step
100: spray dryer
10: drying chamber
11: atomizer
20: piston
21: top plate
23: lower plate
25: heat sink fin
27: hot wire
33: powder outlet
35: gas outlet

Claims (3)

혼합액을 분말화시키는 분무건조기(100)에 있어서,
천장에는 상기 혼합액을 분출하는 아토마이저(11)가 구비되고, 최하단에는 분말배출구(33)가 형성되며, 상기 분말배출구(33)보다 위에 위치하면서 가스(G)가 빠져나가는 가스배출구(35)가 형성되고, 외부에서 뜨거운 공기(H)가 유입되지 않는 원통형의 밀폐된 건조챔버(10); 및,
상기 건조챔버(10) 내에서 상하운동을 함으로써 내압을 조절하고 상판(21)과 하판(23)으로 이루어지며, 상기 상판(21)은 상면이 한쪽으로 기울어지고 상방으로 하나 이상의 방열핀(25)이 구비되며, 상기 하판(23) 내부는 전기적으로 연결된 열선(27)이 구비된 피스톤(20);을 포함하되,
상기 피스톤(20)이 최상에 위치한 경우로서, 상기 건조챔버(10) 내의 온도는 열선(27)의 가열에 의해서만 상승하고 피스톤(20)이 가스배출구(35)보다 높게 있으므로 내부의 가스는 외부로 배출되지 않으며,
상기 피스톤(20)이 최상으로부터 내려오면서 내부 압력을 낮추고 동시에 열선에 의해 건조챔버(10) 내부가 가열됨으로써 기화가 일어나며, 가스배출구(35)의 일부가 개구되지만 분말배출구(33)가 개구되지 않을 때까지는 기화된 가스가 가스배출구(35)를 통해 빠져나가고 분말은 외부로 빠져나가지 않으며,
상기 피스톤(20)이 최하단에 위치하면 분말배출구(33)가 드디어 개구되어 중력에 의해 분말이 상기 한쪽으로 기울어지는 쪽으로 쏟아져 내려가서 외부로 배출되는 것을 특징으로 하는 붓기 개선용 조성물의 생성에 사용되는 분무건조기.
In the spray dryer 100 for powdering the mixed solution,
An atomizer 11 for ejecting the mixture is provided on the ceiling, and a powder outlet 33 is formed at the lowermost end, and a gas outlet 35 through which gas (G) exits while positioned above the powder outlet 33 A sealed drying chamber 10 of a cylindrical shape that is formed and does not introduce hot air (H) from the outside; and;
The internal pressure is adjusted by moving up and down in the drying chamber 10, and the upper plate 21 and the lower plate 23 are formed. It is provided, and the inner part of the lower plate 23 is a piston 20 provided with an electrically connected heating wire 27; including,
When the piston 20 is positioned at the top, the temperature in the drying chamber 10 rises only by heating the heating wire 27 and the piston 20 is higher than the gas outlet 35, so the gas inside is discharged to the outside. not released,
As the piston 20 descends from the top, the internal pressure is lowered and the inside of the drying chamber 10 is heated by the heating wire at the same time to cause vaporization, and a part of the gas outlet 35 is opened, but the powder outlet 33 is not opened. Until the vaporized gas escapes through the gas outlet 35, the powder does not escape to the outside,
When the piston 20 is located at the lowermost end, the powder outlet 33 is finally opened, and the powder is poured down to the side inclined to the side by gravity and discharged to the outside. spray dryer.
원재료를 추출기에 투입하는 투입단계(S10);
상기 추출기에서 원재료를 95~105℃의 온도로 7~9시간동안 추출 후, 다시 14~16시간 동안 침지하는 침지단계(S20);
상기 침지한 원재료를 140~160메쉬의 여과기에서 여과하는 제1 여과단계(S30);
상기 여과된 원재료를 고형분 19~21중량%까지 농축시키는 농축단계(S40);
상기 농축된 원재료인 식물혼합농축액 64~66중량%에 덱스트린 34~36중량%를 혼합하여 혼합액을 만드는 혼합단계(S50);
상기 혼합액을 청구항 1의 분무건조기(100)를 이용하여 분말화하는 분말단계(S60); 및,
상기 분말을 여과기를 이용하여 여과하는 제2 여과단계(S70);를 진행하되,
상기 식물혼합농축액은,
정제수가 92.50~92.51중량%;
대추가 2.36~2.37중량%;
호박이 1.18~1.19중량%;
생강이 0.78~0.79중량%;
돌콩씨앗이 0.63~0.64중량%;
지황뿌리가 0.55~0.56중량%; 및,
참당귀뿌리, 팥, 국화, 귤나무열매껍질 및 대나무잎이 각각 0.39~0.40중량%;를 포함하여 이루어지고,
상기 분말 단계(S60)은 상기 혼합 단계(S50)에서 혼합된 혼합액을 상기 건조 챔버(10)에 구비된 상기 아토아이저(11)를 통해 상기 건조 챔버(10) 내부에 분출하는 단계, 상기 건조 챔버(10) 내부에서 상하 운동하는 피스톤(20)에 의하여 상기 건조 챔버(10)의 내압이 조절되고 상기 건조 챔버(10)가 가열되는 단계, 상기 건조 챔버(10)가 가열되면서 혼합액은 분말과 기화 가스로 분류되는 단계, 상기 피스톤(20)이 하강하여 가스 배출구(35)의 일부가 개구되고 분말 배출구(33)가 개구되지 않은 상태에서 상기 건조 챔버(10)내의 기화 가스가 가스 배출구(35)를 통해 배출되고 상기 건조 챔버(10)내의 분말은 외부로 빠져나가지 않는 단계, 및 상기 피스톤(20)이 상기 건조 챔버(10)내에서 최하단에 위치하여 분말 배출구(33)가 개구되고 중력에 의하여 상기 분말이 외부로 배출되는 단계를 포함하며,
상기 건조 챔버(10)가 가열되는 단계는 상기 피스톤(20)에 구비된 열선(27) 과 방열핀(25)에 의하여 가열되고,
상기 중력에 의하여 상기 분말이 외부로 배출되는 단계는 상기 피스톤(20)의 상판(21)의 상면이 한쪽으로 기울어져서 상기 분말이 중력에 의하여 기울어진 상면을 따라 아래로 이동하는 것을 특징으로 하는 붓기 개선용 조성물의 제조방법.
An input step (S10) of putting the raw material into the extractor;
An immersion step (S20) of extracting the raw material in the extractor at a temperature of 95 to 105° C. for 7 to 9 hours, and then immersing it again for 14 to 16 hours;
A first filtering step (S30) of filtering the immersed raw material in a filter of 140 to 160 mesh;
a concentration step (S40) of concentrating the filtered raw material to a solid content of 19 to 21% by weight;
A mixing step (S50) of mixing 34 to 36 wt% of dextrin with 64 to 66 wt% of the plant mixed concentrate, which is the concentrated raw material, to make a mixed solution (S50);
A powder step (S60) of powdering the mixed solution using the spray dryer 100 of claim 1; and;
A second filtration step (S70) of filtering the powder using a filter; but,
The plant mixture concentrate,
Purified water 92.50 ~ 92.51% by weight;
Jujube 2.36-2.37 wt%;
Pumpkin 1.18 to 1.19 wt%;
Ginger 0.78-0.79 wt%;
Dolphin seeds 0.63 to 0.64% by weight;
0.55 to 0.56% by weight of Rehmannia root; and;
Angelica root, red bean, chrysanthemum, tangerine fruit peel, and bamboo leaf are each 0.39-0.40% by weight;
The powder step (S60) is a step of ejecting the mixed solution mixed in the mixing step (S50) into the drying chamber 10 through the atomizer 11 provided in the drying chamber 10, the drying The internal pressure of the drying chamber 10 is adjusted by the piston 20 moving up and down inside the chamber 10 and the drying chamber 10 is heated. As the drying chamber 10 is heated, the mixture is mixed with powder. In the step of being classified as vaporized gas, the piston 20 descends so that a part of the gas outlet 35 is opened and the vaporized gas in the drying chamber 10 is discharged through the gas outlet 35 ) and the powder in the drying chamber 10 does not escape to the outside, and the piston 20 is located at the lowest end in the drying chamber 10 so that the powder outlet 33 is opened and Including the step of discharging the powder to the outside by
The step of heating the drying chamber 10 is heated by the heating wire 27 and the heat radiation fin 25 provided in the piston 20,
In the step of discharging the powder to the outside by gravity, the upper surface of the upper plate 21 of the piston 20 is inclined to one side, and the powder moves downward along the inclined upper surface by gravity. Method for producing a composition for improvement.
삭제delete
KR1020200165231A 2020-12-01 2020-12-01 Composition for relieving swelling, the spray dryer and the menufacturing method KR102265902B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020200165231A KR102265902B1 (en) 2020-12-01 2020-12-01 Composition for relieving swelling, the spray dryer and the menufacturing method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020200165231A KR102265902B1 (en) 2020-12-01 2020-12-01 Composition for relieving swelling, the spray dryer and the menufacturing method

Publications (1)

Publication Number Publication Date
KR102265902B1 true KR102265902B1 (en) 2021-06-16

Family

ID=76603138

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020200165231A KR102265902B1 (en) 2020-12-01 2020-12-01 Composition for relieving swelling, the spray dryer and the menufacturing method

Country Status (1)

Country Link
KR (1) KR102265902B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230053406A (en) 2021-10-14 2023-04-21 김동배 Food composition containing plants mixture for relieving swell of face and its manufacturing methhod

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100297244B1 (en) * 1998-06-12 2001-10-26 현 용 이 Manufacturing method of instant powder tea using chicory
CN105533694A (en) * 2015-12-17 2016-05-04 劲膳美生物科技股份有限公司 Total-nutrient formula food for pregnant women suffering from oedema
KR102074192B1 (en) 2019-11-07 2020-02-06 주식회사 퍼플랩스헬스케어 Manufacturing method of composition comprising pumpkin seed, beet, maca and aronia for preventing and ameliorating edema and composition thereof
KR20200053014A (en) * 2018-11-07 2020-05-18 이효준 Anti-oxidant composition comprising the mixed extract of vegetable natural products having the effect on removal of swelling
KR20200106577A (en) * 2019-03-04 2020-09-15 헬스밸런스 주식회사 Composition for anti-oxidant, anti-inflammatory and relieving swelling containing plant complex extracts

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100297244B1 (en) * 1998-06-12 2001-10-26 현 용 이 Manufacturing method of instant powder tea using chicory
CN105533694A (en) * 2015-12-17 2016-05-04 劲膳美生物科技股份有限公司 Total-nutrient formula food for pregnant women suffering from oedema
KR20200053014A (en) * 2018-11-07 2020-05-18 이효준 Anti-oxidant composition comprising the mixed extract of vegetable natural products having the effect on removal of swelling
KR20200106577A (en) * 2019-03-04 2020-09-15 헬스밸런스 주식회사 Composition for anti-oxidant, anti-inflammatory and relieving swelling containing plant complex extracts
KR102074192B1 (en) 2019-11-07 2020-02-06 주식회사 퍼플랩스헬스케어 Manufacturing method of composition comprising pumpkin seed, beet, maca and aronia for preventing and ameliorating edema and composition thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
네이버 블로그 (2019.12.01.)* *
중국특허공개공보 105533694(2016.05.04.)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230053406A (en) 2021-10-14 2023-04-21 김동배 Food composition containing plants mixture for relieving swell of face and its manufacturing methhod

Similar Documents

Publication Publication Date Title
DE602004008222T2 (en) VEGETABLE COMPOSITIONS FOR PROSTATE IDEAS
CN108576819A (en) A kind of liver-protecting combination, health food, preparation method and applications
SADIQ SEX REVERSAL OF NILE TILAPIA Oreochromis niloticus (LINNEAUS, 1758) USING DIFFERENTLY PROCESSED Tribulus terrestris L. EXTRACTS
KR102265902B1 (en) Composition for relieving swelling, the spray dryer and the menufacturing method
CN1275639C (en) Medicine for treating women&#39;s habitual abortion and threatened abortion
CN105995249A (en) Banana prawn feed additive and preparation method thereof
Abu et al. Nephrotoxic evaluation of aqueous stem bark extract of Dialium guineense in normal Wistar Rats
CN102228551A (en) Chinese medicinal composition for preventing and treating injury of gastric mucosa and preparation method thereof
Amer et al. Effects of Rosemary and husk on hemogram and some biochemical parameters during treatment of ulcerative colitis in rats
Fang et al. Further studies on the hepatoprotective effects of Anoectochilus formosanus
CN100340266C (en) Jiangzhi capsule good for liver and its preparing process
CN112402511A (en) Traditional Chinese medicine composition for liver health care and application thereof
CN111387502A (en) Propolis-bitter gourd composition with auxiliary blood sugar reducing effect and preparation method thereof
CN113499366A (en) Composition with function of reducing blood sugar and blood fat simultaneously and preparation method thereof
Ajayi et al. Evaluation of the toxicological status of Balanite aegyptiaca seed oil
CN114521648A (en) Food composition with auxiliary protection function on chemical liver injury and preparation method thereof
US8815313B2 (en) Compositions of rose hips enriched with seeds of rose hips and their use as anti-inflammatory natural medicine for alleviating/reducing symptoms associated with inflammation and joint diseases such as arthritis, rheumatoid arthritis and/or osteo-arthritis
KR100462166B1 (en) A extract derived from male pupae before adults of silkworm, a preparation method thereof and foods and pharmaceutical compositions containing the same
Zaman et al. Evaluation of Antifertility Effect of Methanolic Bulb Extract of Allium cepa on Swiss Albino Male and Teratogenic Effect on...
CN109717330A (en) Carp feed and preparation method thereof
Sodipe et al. Effects of Aframomum Melegueta Seed Extract on the Haematological and some Biochemical Parameters in Albino Rats
CN108497494A (en) A kind of health food and preparation method thereof of auxiliary reducing blood lipid
US20030118671A1 (en) Formulation containing peanut leaf extract and its preparation
Emelike et al. Effect of prenatal consumption of Combretum dolichopetalum by pregnant rats on haematological and biochemical parameters as well as pregnancy outcome
Ajayi et al. Short term toxicological analysis and effect of total replacement of wheat with Balanite aegyptiaca seed cake on albino rats

Legal Events

Date Code Title Description
AMND Amendment
AMND Amendment
X701 Decision to grant (after re-examination)
GRNT Written decision to grant